COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2022 and September 30, 2021 is as follows (in thousands):


Nine Months Ended September 30, 2022	Contingent Consideration Liability Related to Acquisition of:
	Arkis				Location in Financial Statements	Derma Sciences		ACell Inc. (See Note 2)				Location in Financial Statements
	Short-term		Long-term			Long-term		Short-term		Long-term
Balance as of January 1, 2022	$	3,691	$	11,408		$	230	$	—	$	21,800
Transfers	—		—			—		4,885		(4,885)
Change in fair value of contingent consideration liabilities	(862)		$	(1,819)	Research and development	—		(4,885)		(11,915)		Selling, general and administrative
Balance as of September 30, 2022	$	2,829	$	9,589		$	230	$	—	$	5,000


Nine Months Ended September 30, 2021	Contingent Consideration Liability Related to Acquisition of:
	Arkis				Location in Financial Statements	Derma Sciences		ACell Inc. (See Note 2)		Location in Financial Statements
	Short-term		Long-term			Long-term		Long-term
Balance as of January 1, 2021	$	3,415	$	11,746		$	230	$	—
Additions from acquisition of ACell	—		—			—		23,900
Transfers	(3,415)		3,415			—		—
Change in fair value of contingent consideration liabilities	—		(544)		Research and development	—		(900)		Selling, general and administrative
Balance as of September 30, 2021	$	—	$	14,617		$	230	$	23,000